Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 08 tags : Trial save search
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
ntact-01 lung immunotherapy trial update cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
Published: 2022-12-08 (Crawled : 22:00) - globenewswire.com
MGTX | $4.87 -1.22% -1.23% 110K
|
Health Technology
|
| O: 1.37%
H: 1.36%
C: -1.69%
trial phase 1
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
Published: 2022-12-08 (Crawled : 16:00) - biospace.com/
RAPT | $7.905 -1.19% -1.2% 290K
|
Health Technology
|
| O: 3.46%
H: 0.0%
C: -4.96%
flx475 trial therapeutics update cancer phase 1
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -1.26%
H: 8.94%
C: 5.53%
life trial
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: -60.42%
H: 0.66%
C: -23.03%
hepatitis virus trial
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Published: 2022-12-08 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.34%
H: 1.98%
C: -1.85%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 2.92%
H: 0.03%
C: -3.66%
treatment ongoing pharmaceuticals trial berubicin glioblastoma
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
Published: 2022-12-08 (Crawled : 14:20) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 4.15%
H: 22.51%
C: 15.95%
bx1000 trial
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial phase 1
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial therapeutics phase 1
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
xl102 sabcs trial tumors results phase 1
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
ANIX | $3.1 0.98% 0.97% 360K
|
Health Technology
|
| O: -0.2%
H: 1.84%
C: -5.33%
vaccine breast trial cancer
HCW Biologics Enters CRADA with National Cancer InstituteNCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HCWB | $1.6036 -1.24% 890
|
|
| O: 4.82%
H: 0.0%
C: -1.48%
hcw9218 trial cancer pancreatic phase 2b
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
Published: 2022-12-08 (Crawled : 13:20) - biospace.com/
INAB | $1.03 -0.96% -0.97% 150K
|
|
| O: 0.81%
H: 2.01%
C: -6.02%
inb-400 fda clearance trial phase 2 glioblastoma
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
Published: 2022-12-08 (Crawled : 13:00) - biospace.com/
CANF | $1.94 -1.52% 0.0% 5.7K
|
Health Technology
|
| O: -0.18%
H: 2.63%
C: -1.32%
treatment osteoarthritis piclidenoson trial
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
Published: 2022-12-08 (Crawled : 13:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.45%
H: 2.13%
C: 0.22%
rgx-111 treatment trial mps-ih mps-i
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 1.82%
H: 1.52%
C: -7.91%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.09%
H: 1.98%
C: 1.82%
medical trial therapeutics phase 1
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
Published: 2022-12-08 (Crawled : 12:20) - biospace.com/
BTTX | $0.006 -65.02% 340K
|
|
| O: -1.41%
H: 8.56%
C: 3.59%
liver disease topline trial therapeutics positive
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
Published: 2022-12-08 (Crawled : 10:00) - biospace.com/
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 3.56%
H: 1.16%
C: -1.27%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: -0.11%
H: 0.71%
C: 0.24%
ioa-289 trial cancer pancreatic
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.